Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two – year results from the First Prospective Randomized Controlled Trial
Ropeginterferon Alfa-2b Induces High Rates of Clinical, Hematological and Molecular Responses in PV Patients. Two – year results from the First Prospective Randomized Controlled Trial